#AAN25: J&J, argenx keep rolling out myasthenia gravis data, plus morenews2025-04-10T14:46:03+00:00April 10th, 2025|Endpoints News|
Alzheon’s amyloid-targeting pill fails another Alzheimer’s Phase 3news2025-04-10T14:40:12+00:00April 10th, 2025|Endpoints News|
Q&A: Lundbeck’s head of R&D on letting ‘biology speak’ in neurosciencenews2025-04-08T14:00:10+00:00April 8th, 2025|Endpoints News|
Cartesian reveals long-term mid-stage data for cell therapy in myasthenia gravisnews2025-04-08T11:01:20+00:00April 8th, 2025|Endpoints News|
Rhythm touts Phase 3 win for rare obesity drug in people with brain damagenews2025-04-07T11:00:53+00:00April 7th, 2025|Endpoints News|
Novavax’s approval delay may signal warning for vaccine makersnews2025-04-04T18:49:03+00:00April 4th, 2025|Endpoints News|
RiboX Therapeutics quietly starts first circular RNA trialnews2025-04-04T14:35:13+00:00April 4th, 2025|Endpoints News|
Arvinas touts healthy volunteer data for Parkinson’s disease PROTACnews2025-04-04T11:00:20+00:00April 4th, 2025|Endpoints News|
Eli Lilly pays struggling Sangamo $18M upfront to tap gene therapy capsidnews2025-04-04T10:53:40+00:00April 4th, 2025|Endpoints News|
Roche plans to take its latest Alzheimer’s drug attempt to Phase 3news2025-04-03T16:16:27+00:00April 3rd, 2025|Endpoints News|
